$39.9 M

KMPH Mkt cap, 10-Jun-2019
KemPharm Net income (Q2, 2019)-9.3 M
KemPharm EBIT (Q2, 2019)-7.8 M
KemPharm Cash, 30-Jun-20197.3 M

KemPharm Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

13.9m20.5m20.6m41.8m

General and administrative expense

8.9m14.0m12.8m12.5m

Operating expense total

22.8m37.5m33.4m55.9m

EBIT

(22.8m)(37.5m)(33.4m)(55.9m)

Interest income

32.0k353.0k365.0k420.0k

Pre tax profit

(54.6m)(16.5m)(43.4m)(56.6m)

Income tax expense

(26.0k)15.0k43.0k126.0k

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)

Quarterly

USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

R&D expense

2.8m3.2m5.0m4.3m4.1m6.3m11.6m10.5m8.5m4.8m

General and administrative expense

3.2m3.7m4.3m3.1m3.3m3.3m3.1m3.4m2.8m3.0m

Operating expense total

6.0m7.0m9.3m10.4m7.4m9.6m14.8m13.9m11.4m7.8m

EBIT

(6.0m)(7.0m)(9.3m)(10.4m)(7.4m)(9.6m)(14.8m)(13.9m)(11.4m)(7.8m)

Interest expense

649.0k

Interest income

102.0k144.0k98.0k101.0k154.0k115.0k123.0k151.0k84.0k

Pre tax profit

(29.7m)(2.9m)9.8m(13.4m)(16.3m)(10.0m)(26.2m)(10.0m)(12.3m)(9.3m)

Income tax expense

(12.0k)4.0k19.0k4.0k4.0k8.0k39.0k8.0k9.0k

Net Income

(29.7m)(2.9m)9.8m(13.4m)(16.3m)(10.0m)(26.2m)(10.0m)(12.3m)(9.3m)

KemPharm Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

32.3m16.8m10.9m18.4m

Inventories

2.8m489.0k

Current Assets

54.1m74.4m47.0m23.7m

PP&E

403.0k2.0m2.0m1.8m

Total Assets

55.7m84.9m52.5m26.7m

Accounts Payable

4.9m6.4m7.9m8.3m

Current Liabilities

8.3m6.6m11.5m12.0m

Total Liabilities

103.6m110.0m93.3m

Additional Paid-in Capital

94.7m102.6m107.2m154.6m

Retained Earnings

(104.8m)(121.3m)(164.7m)(221.2m)

Total Equity

(10.1m)(18.7m)(57.5m)(66.6m)

Financial Leverage

-5.5 x-4.5 x-0.9 x-0.4 x

KemPharm Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)

Depreciation and Amortization

84.0k175.0k336.0k324.0k

Accounts Receivable

(4.5m)

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)(1.6m)

Cash From Operating Activities

(20.3m)(29.8m)(33.1m)(54.2m)

Purchases of PP&E

(135.0k)(643.0k)(181.0k)(21.0k)

Cash From Investing Activities

(19.1m)(46.9m)27.4m33.3m

Cash From Financing Activities

61.5m61.2m(203.0k)28.0m

Interest Paid

3.0k3.3m5.7m5.6m

Quarterly

USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

1.4m

Accounts Payable

4.0m4.9m4.2m5.4m5.6m4.6m6.3m6.4m

KemPharm Ratios

USDY, 2019

Financial Leverage

-0.2 x